Beta Thalassemia Overview
Learn About Beta Thalassemia
View Main Condition: Thalassemia
Beta thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.
Variants (also known as mutations) in the HBB gene cause beta thalassemia. The HBB gene provides instructions for making a protein called beta-globin. Beta-globin is a component (subunit) of hemoglobin. Hemoglobin consists of four protein subunits, typically two subunits of beta-globin and two subunits of another protein called alpha-globin.
Beta thalassemia is a fairly common blood disorder worldwide. Thousands of infants with beta thalassemia are born each year. Beta thalassemia occurs most frequently in people from Mediterranean countries, North Africa, the Middle East, India, Central Asia, and Southeast Asia.
Thalassemia major and thalassemia intermedia are inherited in an autosomal recessive pattern, which means both copies of the HBB gene in each cell have variants. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition. Sometimes, however, people with only one HBB gene variant in each cell develop mild anemia. These mildly affected people are said to have thalassemia minor.
Aurora Internal Medicine
Alok Srivastava is a primary care provider, practicing in Internal Medicine in Waterford, Wisconsin. Dr. Srivastava is rated as an Elite provider by MediFind in the treatment of Beta Thalassemia. His top areas of expertise are Hemophilia A, Blood Clots, Beta Thalassemia, Bone Marrow Aspiration, and Endovascular Embolization.
Antonella Meloni practices in Pisa, Italy. Ms. Meloni is rated as an Elite expert by MediFind in the treatment of Beta Thalassemia. Her top areas of expertise are Thalassemia, Beta Thalassemia, Hemoglobinopathy, Hemolytic Anemia, and Splenectomy.
Maria Cappellini-Domenica practices in Milan, Italy. Ms. Cappellini-Domenica is rated as an Elite expert by MediFind in the treatment of Beta Thalassemia. Her top areas of expertise are Anemia, Thalassemia, Congenital Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.
Summary: This is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Summary: This study is researching an experimental drug called REGN7999 (called study drug). The study is focused on patients with non-transfusion dependent beta-thalassemia. The aim of the study is to see how safe and effective the study drug is. The study is looking at several other research questions, including: * Whether the study drug lowers extra iron levels in the body * What side effects may happen...
Published Date: May 01, 2023
Published By: National Institutes of Health
